NET PROFIT (x1000 SEK)
EMPLOYEES
Vicore Pharma Holding AB
Closing information (x1000 SEK)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover |
0
![]() |
0
![]() |
0 |
Financial expenses |
476
|
2,563
|
6 |
Earnings before taxes |
-288,806
|
-296,735
|
-147,315 |
EBITDA |
-287,368
|
-291,220 | |
Total assets |
338,007
|
451,168
|
406,515 |
Current assets |
269,790
|
377,931
|
327,847 |
Current liabilities |
46,292
|
65,570
|
44,294 |
Equity capital |
289,083
|
383,316
|
354,513 |
- share capital |
40,924
|
35,880
|
25,087 |
Employees (average) |
21
|
16
|
13 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency |
85.5%
|
85.0%
|
87.2% |
Turnover per employee |
0
![]() |
0
![]() |
0 |
Profit as a percentage of turnover | |||
Return on assets (ROA) |
-85.3%
|
-65.2%
|
-36.2% |
Current ratio |
582.8%
|
576.4%
|
740.2% |
Return on equity (ROE) |
-99.9%
|
-77.4%
|
-41.6% |
Change turnover |
0
![]() |
0
![]() |
0 |
Change turnover % | |||
Chg. No. of employees |
5
|
3
|
5 |
Chg. No. of employees % |
31%
|
23%
|
63% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.